PAEDIATRIC ZINC SULFATE ORAL SOLUTION
Revised draft proposal for The International Pharmacopoeia
( September 2007)

DRAFT FOR DISCUSSION

© World Health Organization 2007
All rights reserved.

This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The draft may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means outside these individuals and organizations (including the organizations’ concerned staff and member organizations) without the permission of WHO. The draft should not be displayed on any web site.

Please send any request for permission to:
Dr Sabine Kopp, Quality Assurance & Safety: Medicines (QSM), Department of Medicines Policy and Standards (PSM), World Health Organization, CH-1211 Geneva 27, Switzerland.
Fax: (41-22) 791 4730; e-mails: kopps@who.int; bonnyw@who.int

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.

Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this draft is complete and correct and shall not be liable for any damages incurred as a result of its use.
SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT QAS/07.195

International Pharmacopoeia monograph on Paediatric Zinc Sulfate Oral Solution

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preparation of first draft by laboratory</td>
<td>January-February 2007</td>
</tr>
<tr>
<td>First draft mailed out for comments</td>
<td>end March 2007</td>
</tr>
<tr>
<td>Comments reviewed in Consultation on Specifications for Medicines and Quality Control Laboratory Issues</td>
<td>27-29 June 2007</td>
</tr>
<tr>
<td>Contact with laboratory concerning specific issues to be resolved</td>
<td>August 2007</td>
</tr>
<tr>
<td>Second draft prepared</td>
<td>September 2007</td>
</tr>
<tr>
<td>Presentation to WHO Expert Committee on Specifications for Pharmaceutical Preparations for possible adoption</td>
<td>15-19 October 2007</td>
</tr>
</tbody>
</table>

[Note from the Secretariat: Preparation of the zinc monographs was initiated because zinc supplementation is included in the revised WHO/UNICEF recommendations for the management of diarrhoea as an adjunct to oral rehydration therapy.]
PAEDIATRIC ZINC SULFATE ORAL SOLUTION
Revised draft proposal for *The International Pharmacopoeia*
(September 2007)

[Note from the Secretariat: The term "paediatric" has been included in the title of this monograph since this oral solution is included in the 15th WHO Model list of essential medicines (March 2007) under "medicines for diarrhoea in children" (section 17.5.2).]

**Category.** Adjunct to oral rehydration salts in (prevention and) treatment of dehydration due to diarrhoea.

**Storage.** Paediatric zinc sulfate oral solution should be kept in a well-closed container.

**Labelling.** The designation of the container of Paediatric zinc sulfate oral solution should indicate the quantity in terms of the equivalent amount of elemental zinc.

**Additional information.** Strength in the current WHO Model list of essential medicines: 10 mg of zinc (as zinc sulfate monohydrate or zinc sulfate heptahydrate) per 5 ml. Additional strength available: 20 mg of zinc (as zinc sulfate monohydrate or zinc sulfate heptahydrate) per 5 ml.

[Note from the Secretariat. This additional strength is given since, although not in the EML, it is included in the WHO/UNICEF Guidelines on Production of Zinc tablets and Zinc Oral Solution.]

**Requirements**

Complies with the monograph for "Liquid Preparations for Oral Use".

**Definition.** Paediatric zinc sulfate oral solution is a solution of Zinc Sulfate as the monohydrate or heptahydrate in a suitable flavoured vehicle. It contains not less than 90.0% and not more than 110.0% of the amount of zinc stated on the label.

**Manufacture.** The formulation of the oral solution and the manufacturing process are designed and controlled so as to ensure that the metallic taste of the zinc salt is adequately masked.

**Identity tests**

A. To 5 ml add 0.2 ml of sodium hydroxide (400 g/l) TS. A white precipitate is formed. Add a further 2 ml of sodium hydroxide (400 g/l) TS. The precipitate dissolves. Add 10 ml of ammonium chloride (100 g/l) TS. The solution remains clear. Add 0.1 ml of sodium sulfide TS. A flocculent white precipitate is formed.

B. Five ml yields reaction A described under 2.1 General identification tests as characteristic of sulfates.

**pH value.** (1.13) pH of the oral solution: 2.5 - 4.5.
Relative density. (1.3) Relative density of the oral solution: 1.18 - 1.24.

Assay. To a quantity of the oral solution equivalent to about 10 mg of zinc, accurately measured, add 50 ml of water R and 5 ml of ammonia buffer TS and titrate with disodium edetate (0.01 mol/l) VS using about 50 mg of Mordant Black 11 indicator mixture R as indicator. Each ml of disodium edetate (0.05 mol/l) VS is equivalent to 3.27 mg of zinc.

***